Section I - IDENTIFY

Common/Trade Name: Prochlorperazine Edisylate Injection (5 mg/ml, 2 and 10 ml vials)
Chemical Names: Phenothiazine, 2-chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-, ethanedisulfonate
Synonyms: 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine edisylate, 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine 1,2-ethanedisulfonate, Prochlorperazine ethane disulfonate
Manufacturer's Name: BEN VENUE LABORATORIES, INC.
Address: 300 NORTHFIELD ROAD
BEDFORD, OH 44146
Emergency Telephone Number: Chemtrec: 1(800)424-9300
Telephone Number for Info.: (440)232-3320 -or- (800)562-4797
Medical Emergency: Professional Services 1(800)521-5169
Date Prepared: July 21, 2004

Section II - HAZARDOUS INGREDIENTS/COMPOSITION INFORMATION

<table>
<thead>
<tr>
<th>Component</th>
<th>%</th>
<th>CAS#</th>
<th>OSHA PEL</th>
<th>ACGIH TLV</th>
<th>Other Limits Recommended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prochlorperazine Edisylate</td>
<td>0.7</td>
<td>1257-78-9</td>
<td>NONE</td>
<td>NONE</td>
<td>NONE</td>
</tr>
<tr>
<td>Sodium Phosphate Monobasic</td>
<td>0.6</td>
<td>7558-80-7</td>
<td>NONE</td>
<td>NONE</td>
<td>NONE</td>
</tr>
<tr>
<td>Sodium Tartrate Dihydrate</td>
<td>1.4</td>
<td>6106-24-7</td>
<td>NONE</td>
<td>NONE</td>
<td>NONE</td>
</tr>
<tr>
<td>Sodium Saccharin</td>
<td>0.09</td>
<td>1 28-44-9</td>
<td>NONE</td>
<td>NONE</td>
<td>NONE</td>
</tr>
<tr>
<td>Benzyl Alcohol</td>
<td>0.7</td>
<td>100-51-6</td>
<td>NONE</td>
<td>NONE</td>
<td>NONE</td>
</tr>
<tr>
<td>Water for Injection</td>
<td>96.5</td>
<td>7732-18-5</td>
<td>NONE</td>
<td>NONE</td>
<td>NONE</td>
</tr>
</tbody>
</table>

Prochlorperazine Edisylate Injection is a sterile injectable liquid drug provided in a vial.

Section III - HEALTH HAZARD DATA

Routes of Entry: Prochlorperazine Edisylate Injection may be absorbed via contact with skin or eyes, inhalation of aerosols or accidentally ingested. Under normal use with supervision of a physician, Prochlorperazine Edisylate Injection presents little hazard.

Health Hazard (Acute & Chronic): Prochlorperazine Edisylate Injection is used for the treatment of severe nausea and vomiting and the management of the manifestation of psychotic disorders. Minimal adverse effect should occur from routine handling of this product. Acute signs and symptoms of over exposure by injection or ingestion on may include drowsiness, dizziness, restlessness, severe muscle spasms, blurred vision, hypotension, cholestatic jaundice, seizures or women may experience menstrual irregularities. Product may cause allergic reactions in individuals sensitive to phenothiazines.
Medical Conditions Generally Aggravated by Exposure: Conditions aggravated by exposure may include nervous system disorders.

Carcinogenicity: NTP? NO  IARC Monographs? NONE  OSHA Regulated? NO

Signs & Symptoms of Exposure: Exposure can cause irritation to eyes, skin, and respiratory system, nausea, headache, or dizziness.

BVL Hazard Category: 3

Section IV - FIRST AID MEASURES

Eye Exposure: Flush eyes with large volumes of water for 15 or more minutes. Get medical attention if irritation or signs of exposure are noted.

Skin Exposure: Remove contaminated clothing, wash skin with water and soap for 15 minutes. Get medical attention if irritation or signs of exposure are noted.

Ingestion: If ingestion occurs, flush mouth with water and seek medical attention immediately. Never give anything by mouth to an unconscious person.

Injection: In cases of accidental injection, wash and disinfect area, get medical attention.

Inhalation: If difficulty with breathing, remove from exposure, administer oxygen. Seek attention of a physician immediately. When appropriate and trained in CPR, provide artificial respiration.

Section V - FIRE AND EXPLOSION HAZARD DATA

Flash Point (Method Used): Not Applicable  LEL: Not Applicable  UEL: Not Applicable

Flammable Limits: Not Applicable

Extinguishing Media: Use water or an ABC multi-purpose extinguisher.

Special Fire Fighting Procedures: As with all fires, evacuate personnel to a safe area. Fire fighters should wear self-contained breathing apparatus to avoid inhalation of smoke. Product is aqueous-based and is not expected to present a fire hazard concern.

Unusual Fire/Explosion Hazards: Heat of the fire could cause vials or syringes to burst.

Section VI - ACCIDENTAL RELEASE INFORMATION

Release to Land: Absorb Prochlorperazine Edisylate Injection with absorbent materials and dispose according to local, state, and federal guidelines.

Release to Air: If aerosolized, reduce exposures by ventilating area.

Release to Water: Refer to local water authority. Drain disposal is not recommended; refer to local, state, and federal disposal guidelines.

Section VII - PRECAUTIONS FOR SAFE HANDLING AND USE

Steps to be taken in case material is released or spilled: See Section VI above.

Wear latex or nitrile gloves and safety glasses when cleaning spills. A dust/mist respirator (N95) may be necessary if excessive aerosols are generated.

Waste Disposal Method: Incineration in an approved incinerator is recommended. Refer to local, state, and federal rules.

Precautions to be taken in handling and storing: Store at controlled room temperature 15°-30°C (59°-86°F). Keep away from direct light. Follow instructions provided in packaging.

Other Precautions: None identified.
Section VIII - CONTROL MEASURES AND PERSONAL PROTECTIVE EQUIPMENT

Respiratory Protection: Under normal use, respirators are not required. If aerosols are generated, a disposable dust/mist respirator (N95) may be used. Personnel wearing respirators should be fit tested and approved for respirator use under the OSHA Respiratory Protection Standard 29 CFR 1910.134.

Ventilation: Handle product in a well-ventilated area.

Protective Gloves: Latex or nitrile

Eye Protection: Safety glasses

Other Protective Clothing or Equipment: Lab Coat

Work/Hygienic Practices: Wash hands following use. No eating, drinking, or smoking while handling this product.

Section IX - PHYSICAL/CHEMICAL CHARACTERISTICS

Physical State: Liquid
Appearance and Odor: Clear solution
Boiling Point: Not available
Vapor Pressure: Not available
Vapor Density: Not available
Specific Gravity: Not available
Melting Point: Not available
Evaporation Rate: Approx. to water
Solubility in Water: Soluble
pH: 4.2 – 6.2

Section X - STABILITY AND REACTIVITY DATA

Stability: Stable

Incompatibility (Materials to Avoid): None identified.

Hazardous Decomposition or Byproducts: Decomposition products of this compound may include potentially hazardous byproducts such as oxides of carbon, nitrogen, hydrochloric and sulfuric acids at high temperatures.

Hazardous Polymerization: Will not occur

Conditions to Avoid: None identified.

Section XI - TOXICOLOGICAL INFORMATION

For Prochlorperazine Edisylate Injection (active ingredient) RTECS Number XZ4810000

LD₅₀ mouse, Intraperitoneal = 177 mg/kg
LD₅₀ mouse, Subcutaneous = 320 mg/kg
LD₅₀ mouse, Oral = 400 mg/kg

Additional reproductive health data is available from the National Institute for Occupational Safety and Health (NIOSH) Registry of Toxic Effects of Chemical Substances (RTECS).

Section XII - ENVIRONMENTAL IMPACT INFORMATION

Information is currently not available on the environmental impact of Prochlorperazine Edisylate Injection. Handle in a manner to prevent spills or releases to the environment.
Section XIII - DISPOSAL INFORMATION

Dispose of by incineration at an approved/permitted incinerator. Review local, state, and federal regulations for your regulatory area.

Section XIV - TRANSPORTATION INFORMATION

Prochlorperazine Edisylate Injection is not a DOT hazardous material. Prochlorperazine Edisylate Injection is not a DOT Marine Pollutant.

Section XV - REGULATORY INFORMATION

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>SARA 313 listed?:</td>
<td>NO</td>
</tr>
<tr>
<td>CERCLA listed?:</td>
<td>NO</td>
</tr>
<tr>
<td>RCRA listed?:</td>
<td>NO</td>
</tr>
<tr>
<td>TSCA Inventory</td>
<td>NO</td>
</tr>
</tbody>
</table>

Section XVI - OTHER DATA

1. Use of this product should be through or under the direction of a physician. This MSDS does not address therapeutic use of this material.

2. Persons administering this drug to patients must be careful to avoid needle sticks to syringes and other sharps used in the administration. All needle sticks must be reported to your company management.

The information provided is believed to be complete and accurate. It is the user's responsibility to use the information according to their application. Bedford Laboratories and Ben Venue Labs, Inc. assumes no additional liability or responsibility resulting from the use of or reliance on this information.